Longitudinal observation of ocular biometric parameters after intravitreal ranibizumab injection for retinopathy of prematurity
10.3980/j.issn.1672-5123.2026.9.01
- VernacularTitle:早产儿视网膜病变玻璃体腔注射雷珠单抗后眼部生物测量参数的纵向观察
- Author:
Jing YANG
1
;
Qian WANG
1
;
Conghui LI
1
;
Le ZHANG
1
Author Information
1. Department of Ophthalmology, Northwest Women and Children's Hospital, Xi'an 710061, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
ranibizumab;
retinopathy of prematurity;
ocular biometric parameter
- From:
International Eye Science
2026;26(9):1501-1505
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To assess the longitudinal changes in ocular biometric parameters after intravitreal ranibizumab(IVR)injection for the treatment of retinopathy of prematurity(ROP)in premature infants during the first year of life.METHODS:A longitudinal observational and comparative study was conducted on premature infants diagnosed with type 1 ROP, with a one-year follow-up. In treatment group, patients were administered with ranibizumab injection. The control group was set up without any intervention. All the patients were examined by A-scan ultrasound biometry at 0(40 gestational wk), 3, 6, and 12 mo of corrected gestational age(GA). Anterior chamber depth(ACD), lens thickness(LT), vitreous chamber depth(VCD), and axial length(AL)were measured. Anterior segment(AST)was calculated by summing up the ACD and LT.RESULTS:A total of 60 premature infants(60 eyes)were enrolled in this study, with a mean postmenstrual age of 36.80±2.86 wk, including 30 cases(30 eyes)in the treatment group and 30 cases(30 eyes)in the control group. The mean birth weight was 1157.50±232.12 and 1327.00±432.92 g, and the mean GA was 28.46±1.70 and 30.25±2.12 wk in treatment and control groups, respectively. No significant differences were found in all parameters at baseline(P>0.05). However, after correcting GA by 3, 6, and 12 mo, ACD was significantly greater than that of the control group at the 3rd, 6th, and 12th mo. LT was significantly thinner in the treatment group at the 3rd and 6thmo, but no statistically significant difference was observed between the two groups by the 12th mo. Throughout the follow-up period, AST, VCD, and AL were no significant differences in two groups(all P>0.05).CONCLUSION:Ranibizumab administered for the treatment of ROP only affected on ACD and LT. No significant effects are observed on AST, VCD, and AL during the first year of life.
